Nerve root sleeve injections in patients with failed back surgery syndrome: a comparison of three solutions.
OBJECTIVE
To evaluate outcome in patients with failed back surgery syndrome treated with nerve root sleeve injections.


METHODS
An open, nonblinded, randomized study on 60 patients with documented fibrosis in fewer than three nerve roots.


METHODS
After random selection, 20 patients were injected with 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A), another 20 were treated with 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (Depo Medrol) per nerve root (group B), and a third group was treated with bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C). The volume of each injection was 2 ml. The injections were given twice at an interval of 1 week.


METHODS
The patients were evaluated on a verbal pain rating scale 1, 3, and 6 months after the second injection. The Kruskal-Wallis test was used to detect statistically significant differences among the three groups, and the analysis was refined with the Friedman test.


CONCLUSIONS
Overall, although injections induced analgesia at 1 month, these effects were reduced at 3- and 6-month follow-ups. No statistical differences were found between the three treatment groups (after 1 month, p = 0.71; after 3 months, p = 0.69; after 6 months, p = 0.66. The Friedman test showed a significant decrease in treatment score as a function of time in groups B and C (p = 0.015) but not in group A (p = 0.074). Corticosteroids seem responsible for the last phenomenon.
Devulder
J
J
Department of Anesthesia, University Hospital of Gent, Belgium.
Deene
P
P
De Laat
M
M
Van Bastelaere
M
M
Brusselmans
G
G
Rolly
G
G
D000328:Adult; D000368:Aged; D000698:Analgesia / Q000379:methods*; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy* / Q000209:etiology; D002045:Bupivacaine / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005355:Fibrosis; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D007405:Intervertebral Disc Displacement / Q000150:complications / Q000601:surgery*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D013126:Spinal Nerve Roots; D013577:Syndrome
D000779:Anesthetics, Local; D000893:Anti-Inflammatory Agents; D006821:Hyaluronoglucosaminidase; D008775:Methylprednisolone; D002045:Bupivacaine